Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cooling device offers new hope for migraine sufferers

NCT ID NCT06874361

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a device called Mi-Helper that cools the inside of the nose to treat migraine headaches at home. 156 adults with migraines used either the real device or a fake one. The goal was to see if the device could safely relieve pain and other bothersome symptoms within two hours.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

156 people

The number who actually took part.

Started

Mar 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age of 18 to 70 years, inclusive, of either sex at birth. 2. Lives in the contiguous United States. 3. Self-reported to be able to read and understand English sufficiently to provide electronic Informed Consent. 4. Diagnosis of migraine with or without aura for at least 1 year. 5. Individual experiences 2 to 8 migraine attacks per month documented via migraine eDiary during screening. 6. Migraine onset before 50 years of age, self-reported during screening. 7. Migraine preventive medication unchanged for 4 weeks prior to study enrollment. 8. Stated willingness to comply with all study procedures and availability for the duration of the study. 9. Individuals that own a functioning smartphone device, internet connection (Wi-Fi or data plan) and are willing to download the study app. Exclusion Criteria: 1. Participant has difficulty distinguishing his or her migraine attacks from other types of headaches such as tension, exertion, cluster, hormonal or sinus headaches. 2. Participant has 15 or more headache days per month reported via migraine eDiary and during screening. 3. Participant using any opioid medication at the time of screening. 4. Participant has received Botox treatment, barbiturates, SPG block, nerve blocks or trigger point injections in the head or neck within the last 4 weeks of screening. 5. Participant lives at an altitude of 2000 meters or more above sea level. 6. Self-reported intolerance to intranasal therapy. 7. Self-reported recurrent epistaxis or chronic rhinosinusitis. 8. Self-reported sinus or intranasal surgery within the last 4 months of screening. 9. Self-reported history of 'complicated migraine or headaches' (i.e., hemiplegic migraine, ophthalmoplegic migraine, migrainous infarction, basilar migraine, post-traumatic headaches, post-concussion syndrome). 10. Known or suspected pregnancy as self-reported by the prospective participant at the time of screening. 11. Prospective participant unable to fully understand the consent process and provide informed consent due to either language barriers or mental capacity. 12. Self-reported diagnosis of alcohol or substance abuse disorder at the time of screening. 13. Participant with active chronic pain syndromes, such as fibromyalgia, chronic pelvic pain, or Complex Regional Pain Syndrome (CRPS); or other pain syndrome like trigeminal neuralgia. 14. Participant with severe uncontrolled psychiatric conditions or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments. 15. Failure to adhere to or inability to complete Study App inputs and onboarding activities during the screening period. Participants who are not adherent during the screening period are not eligible for study entry. 16. Participation in a previous clinical study with the Mi-Helper device. 17. Participation in a migraine study or any other interventional clinical study within the3 months prior to screening. 18. Participant has an uncontrolled medical issue at the time of screening. 19. Any condition for which transnasal air flow would be contraindicated, as determined by the Principal Investigator (PI).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • SPRIM Pro

    Indian Harbour Beach, Florida, 32937, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.